Children who are overweight or obese have 3 times as much risk of high blood pressure as children of normal weight have, reported a study published recently in Hypertension: Journal of the American Heart Association.
Children who are overweight or obese are at triple the risk faced by children of normal weight when it comes to blood pressure risk, reported a study published recently in Hypertension: Journal of the American Heart Association.
Researchers at the Indiana University (IU) School of Medicine in Indianapolis, Ind., examined 1,111 healthy Indiana schoolchildren over a period of 4.5 years. They found that when the children’s body mass index (BMI) reached or passed the 85th percentile - the beginning of the overweight category - the effect of adiposity (fat under the skin and surrounding major organs) on blood pressure was more than 4 times that for children of normal weight.
Among the study participants, 14% of overweight/obese children had blood pressure measurements in prehypertensive or hypertensive levels, compared to 5% of children of normal weight.
“Higher blood pressure in childhood sets the stage for high blood pressure in adulthood,” said Wanzhu Tu, PhD, lead author of the study and professor of biostatistics at the IU School of Medicine. “Targeted interventions are needed for these children. Even small decreases in BMI could yield major health benefits.”
Future study may determine how the increase in adiposity affects blood pressure and whether other factors such as leptin, insulin, or inflammatory cytokines may play a role. “The adiposity effects on blood pressure in children are not as simple as we thought,” Tu said.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.